BERKELEY, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) , a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call today, Monday, June 30, 2014, at 4:30 p.m. Eastern time to confirm the communication plan for its EYEGUARD™-B clinical program.
Incyte Corporation (Nasdaq: INCY) today reported 2014 second-quarter
financial results, including revenue from Jakafi ®
(ruxolitinib), which is approved by the U.S. Food & Drug Administration
(FDA) for the treatment of patients with intermediate or high-risk
myelofibrosis (MF). The Company highlighted its strong financial
position, driven by growing Jakafi sales in the U.S. and Jakavi ®
(ruxolitinib) royalties outside the U.S., as well as the submission of
the ruxolitinib supplemental New Drug Application (sNDA) in the U.S. for
patients with uncontrolled polycythemia vera (PV). The Company also
discussed its expanding clinical pipeline, which includes pivotal as
well as proof of concept studies, and the multiple data presentations
for the Company’s product candidates that were made at the recent
American Society of Clinical Oncology (ASCO) meeting.
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014
BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation (NYSE:XON) to include chimeric antigen receptor T-cell (CAR-T) therapy.
Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO , July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June.
TORONTO , July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today
announced that the Food and Drug Administration (FDA) completed its
review and cleared the company's Investigational New Drug (IND)
application of LOR-253 for the treatment of hematologic malignancies
including acute myeloid leukemia (AML), high-risk myelodysplastic
syndromes (MDS), lymphomas and multiple myeloma.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.